JP2024514703A - ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 - Google Patents
ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 Download PDFInfo
- Publication number
- JP2024514703A JP2024514703A JP2023564639A JP2023564639A JP2024514703A JP 2024514703 A JP2024514703 A JP 2024514703A JP 2023564639 A JP2023564639 A JP 2023564639A JP 2023564639 A JP2023564639 A JP 2023564639A JP 2024514703 A JP2024514703 A JP 2024514703A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- fluoroalkyl
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110439238 | 2021-04-22 | ||
| CN202110439238.4 | 2021-04-22 | ||
| PCT/CN2022/087652 WO2022222921A1 (zh) | 2021-04-22 | 2022-04-19 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514703A true JP2024514703A (ja) | 2024-04-02 |
| JP2024514703A5 JP2024514703A5 (enExample) | 2025-04-28 |
Family
ID=83721971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564639A Pending JP2024514703A (ja) | 2021-04-22 | 2022-04-19 | ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336624A1 (enExample) |
| EP (1) | EP4328224A4 (enExample) |
| JP (1) | JP2024514703A (enExample) |
| KR (1) | KR20230175225A (enExample) |
| CN (1) | CN117279916B (enExample) |
| AU (1) | AU2022261011A1 (enExample) |
| BR (1) | BR112023021383A2 (enExample) |
| CA (1) | CA3213029A1 (enExample) |
| MX (1) | MX2023012361A (enExample) |
| WO (1) | WO2022222921A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11591331B2 (en) | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| WO2022222965A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| EP4410792A4 (en) * | 2021-09-30 | 2025-12-03 | Xizang Haisco Pharmaceutical Co Ltd | NITROGEN-CONTAINS HETEROCYCLIC DERIVATIVE FOR USE AS A PARP INHIBITOR AND ITS USE |
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| CN118434725B (zh) * | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| EP4534537A4 (en) * | 2022-05-25 | 2025-12-10 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLE-DERIVED PARP INHIBITOR AND ITS USE |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| CN117946074A (zh) * | 2022-10-20 | 2024-04-30 | 上海海和药物研究开发股份有限公司 | 具有parp1抑制活性的化合物及其用途 |
| JP2025535834A (ja) * | 2022-11-02 | 2025-10-28 | スアンズ バイオファーマシューティカル カンパニー，リミテッド | 多環式ポリ（ａｄｐリボース）ポリメラーゼ選択的阻害剤 |
| AU2023412594A1 (en) * | 2022-12-23 | 2025-07-10 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| WO2024213111A1 (zh) * | 2023-04-14 | 2024-10-17 | 微境生物医药科技(上海)有限公司 | Parp抑制剂、其制备方法及医药用途 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012515786A (ja) * | 2009-01-23 | 2012-07-12 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| JP2012522007A (ja) * | 2009-03-27 | 2012-09-20 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| JP2018521033A (ja) * | 2015-06-09 | 2018-08-02 | ジェ イル ファーマシューティカル カンパニー リミテッド | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
| JP2020512298A (ja) * | 2016-12-30 | 2020-04-23 | ミトブリッジ，インコーポレーテッド | ポリ−ａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤 |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| CN117177972A (zh) * | 2021-04-19 | 2023-12-05 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| US11591331B2 (en) * | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| WO2022222966A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
-
2022
- 2022-04-19 EP EP22791028.8A patent/EP4328224A4/en active Pending
- 2022-04-19 MX MX2023012361A patent/MX2023012361A/es unknown
- 2022-04-19 AU AU2022261011A patent/AU2022261011A1/en active Pending
- 2022-04-19 US US18/281,855 patent/US20240336624A1/en active Pending
- 2022-04-19 JP JP2023564639A patent/JP2024514703A/ja active Pending
- 2022-04-19 BR BR112023021383A patent/BR112023021383A2/pt unknown
- 2022-04-19 WO PCT/CN2022/087652 patent/WO2022222921A1/zh not_active Ceased
- 2022-04-19 KR KR1020237038365A patent/KR20230175225A/ko active Pending
- 2022-04-19 CN CN202280029738.3A patent/CN117279916B/zh active Active
- 2022-04-19 CA CA3213029A patent/CA3213029A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012515786A (ja) * | 2009-01-23 | 2012-07-12 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| JP2012522007A (ja) * | 2009-03-27 | 2012-09-20 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| JP2018521033A (ja) * | 2015-06-09 | 2018-08-02 | ジェ イル ファーマシューティカル カンパニー リミテッド | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
| JP2020512298A (ja) * | 2016-12-30 | 2020-04-23 | ミトブリッジ，インコーポレーテッド | ポリ−ａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤 |
| WO2021013735A1 (en) * | 2019-07-19 | 2021-01-28 | Astrazeneca Ab | Parp1 inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| JEFFREY W. JOHANNES ET AL.: "Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylp", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 19, JPN6025040755, 27 September 2021 (2021-09-27), pages 14498 - 14512, ISSN: 0005703497 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240336624A1 (en) | 2024-10-10 |
| MX2023012361A (es) | 2023-10-31 |
| BR112023021383A2 (pt) | 2023-12-19 |
| EP4328224A1 (en) | 2024-02-28 |
| CN117279916A (zh) | 2023-12-22 |
| WO2022222921A1 (zh) | 2022-10-27 |
| AU2022261011A1 (en) | 2023-11-16 |
| CA3213029A1 (en) | 2022-10-27 |
| KR20230175225A (ko) | 2023-12-29 |
| EP4328224A4 (en) | 2025-06-18 |
| CN117279916B (zh) | 2026-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514703A (ja) | ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 | |
| CN113767103B (zh) | 新型螺环类K-Ras G12C抑制剂 | |
| JP7850663B2 (ja) | スピロ環含有キナゾリン化合物 | |
| JP7773987B2 (ja) | スピロ環含有キナゾリン化合物 | |
| CN114901661B (zh) | 新型K-Ras G12C抑制剂 | |
| CN118434725B (zh) | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 | |
| CN114149423B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| WO2023061406A1 (zh) | 含三并环结构的parp抑制剂、及其制备方法和医药用途 | |
| JP7796674B2 (ja) | Ｗｅｅ－１阻害剤としてのピラゾロ［３，４－ｄ］ピリミジン－３－オン誘導体 | |
| KR100281867B1 (ko) | 3-(비스-치환페닐메틸렌)옥신돌유도체 | |
| JP2004250329A (ja) | イサチン誘導体 | |
| CN113880804A (zh) | 新型苯并咪唑化合物 | |
| RU2857202C2 (ru) | Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение | |
| WO2024235218A1 (zh) | Hdac1/2选择性抑制剂及其用途 | |
| TWI845843B (zh) | 新型吡嗪化合物 | |
| JP2024524933A (ja) | Ｉｄｈ変異体阻害剤およびその使用 | |
| CN115768775B (zh) | Idh突变体抑制剂及其用途 | |
| CN118108704A (zh) | Kif18a抑制剂 | |
| RU2860311C2 (ru) | Ингибитор мутанта idh и его применение | |
| WO2024213111A1 (zh) | Parp抑制剂、其制备方法及医药用途 | |
| CN121517424A (zh) | PI3Kα抑制剂及其制备方法和医药用途 | |
| JP2024105489A (ja) | Μｇａτ２阻害活性を有する縮合環誘導体の製造方法 | |
| JP2025540298A (ja) | Ｈｄａｃ阻害剤およびその使用 | |
| WO2022228511A1 (zh) | 作为Wee-1抑制剂的稠环化合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250418 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250418 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260107 |